Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. bioinformatics analysis software
Show results for
Products
Services
Software
Training
Applications

Companies

News
Articles
Books
Downloads
Videos

Refine by
Date

  • Older

Bioinformatics Analysis Software Articles & Analysis

34 news found

CD BioGlyco Launches New Glycosyl Derivatization Service for Research Use

CD BioGlyco Launches New Glycosyl Derivatization Service for Research Use

Additionally, low sensitivity in glycan analysis is a drawback for amperometry and refractive index detection. ...

ByCD BioGlyco.


CD ComputaBio Releases AutoDock Vina Software to Accelerate Molecular Docking Projects

CD ComputaBio Releases AutoDock Vina Software to Accelerate Molecular Docking Projects

CD ComputaBio, a reliable computational biology service provider in New York, is committed to assisting research and trials, as well as providing access to the latest software, technologies, and expertise with competitive prices and fast turnarounds for researchers. The company has recently announced the introduction of its Autodock Vina software, designed to predict the mechanism of small ...

ByCD ComputaBio


CD ComputaBio Introduces PyMOL Software for Bioinformatics Analysis

CD ComputaBio Introduces PyMOL Software for Bioinformatics Analysis

The company has announced the introduction of the PyMOL software, a powerful utility for studying proteins, DNA, and other biological molecules, to support bioinformatics analysis and drug design research. ...

ByCD ComputaBio


Mariola Fotin-Mleczek, PhD, has joined Ardigen’s Scientific Board to support the drug discovery process for cancer immunology therapies

Mariola Fotin-Mleczek, PhD, has joined Ardigen’s Scientific Board to support the drug discovery process for cancer immunology therapies

Ardigen, one of the world’s leading companies that utilizes artificial intelligence (AI) algorithms for drug discovery, is proud to announce that Mariola Fotin-Mleczek, PhD, has joined Ardigen’s Scientific Board. Her knowledge and experience will support a deeper understanding of active cancer immunotherapies in the drug discovery process provided by scientific innovation. Mariola ...

ByArdigen


Profacgen Updated Its In Silico Protein-protein Interactions Prediction Service

Profacgen Updated Its In Silico Protein-protein Interactions Prediction Service

Profacgen, a biotechnology company that offers bioinformatics platform to help academic and industrial researchers to explore, understand and analyze complex biological data in various biotechnological programs and projects, recently updated its in silico protein-protein interactions prediction service to meet diversified needs of its customers. ...

ByProfacgen


DNAnexus to Showcase Platform Scalability, Versatility, and Security at ASHG 2022 Annual Meeting

DNAnexus to Showcase Platform Scalability, Versatility, and Security at ASHG 2022 Annual Meeting

DNAnexus, Inc., the leading provider of cloud-based genomic and biomedical data access and companion analysis software, today announced the speaker lineup for its customer presentations at the American Society of Human Genetics (ASHG) 2022 Annual Meeting, which is being held in Los Angeles this week. ...

ByDNAnexus, Inc.


Agnieszka Blum, MD, PhD has been promoted to the Management Board of Ardigen to strengthen drug discovery expertise

Agnieszka Blum, MD, PhD has been promoted to the Management Board of Ardigen to strengthen drug discovery expertise

Ardigen, a global leader in artificial intelligence for drug discovery, is proud to announce that Agnieszka Blum, MD, PhD has joined the company’s Board of Management. She brings with her extensive knowledge and experience in the field of Immuno-Oncology and drug discovery, which is strategic for Ardigen’s development. Agnieszka Blum, MD, PhD will continue her mission as the General ...

ByArdigen


Prof. Dr. med. Michael Schmitt, MHBA has joined Ardigen`s Scientific Board to support the development of AI platforms for cell therapy discovery

Prof. Dr. med. Michael Schmitt, MHBA has joined Ardigen`s Scientific Board to support the development of AI platforms for cell therapy discovery

Ardigen, one of the world-leading companies that utilizes artificial intelligence (AI) algorithms for drug discovery, is proud to announce that Prof. Dr. Michael Schmitt, MHBA, has joined the company’s Scientific Advisory Board. His knowledge and experience will support work on artificial intelligence-based platforms, dedicated to accelerating and optimizing the discovery of novel cell ...

ByArdigen


OncoDNA Announces the Operational Launch of its OncoDEEP Kit for Comprehensive Genomic Profiling of Solid Tumors

OncoDNA Announces the Operational Launch of its OncoDEEP Kit for Comprehensive Genomic Profiling of Solid Tumors

A UNIQUE WORKFLOW SOLUTION INTEGRATING A PAN-CANCER NEXT-GENERATION SEQUENCING (NGS) PANEL POWERED BY A BIOINFORMATICS SOFTWARE SUITE FOR CUSTOMIZABLE BIOLOGICAL AND CLINICAL INTERPRETATION ONCODNA, A GENOMIC AND THERANOSTIC COMPANY SPECIALIZING IN PRECISION MEDICINE FOR THE TREATMENT OF CANCER AND GENETIC DISEASES, TODAY ANNOUNCED THE OFFICIAL LAUNCH OF THE ...

ByOncoDNA S.A.


Molecular Health receives IVDR certification for MH Guide

Molecular Health receives IVDR certification for MH Guide

Molecular Health, an international biotech IT company based in Heidelberg, Germany, has received European Union certification for its MH Guide clinical decision support software (SaaS) under the new In Vitro Diagnostics Regulation (EU) 2017/746 (IVDR). The MH Guide software, which is used in molecular pathology laboratories, is the first of its kind in Europe to receive this certification. The ...

ByMolecular Health GmbH


Molecular Health and collaborators prove new analytical approach that leverages real-world data to anticipate molecular causation of adverse drug reactions

Molecular Health and collaborators prove new analytical approach that leverages real-world data to anticipate molecular causation of adverse drug reactions

“We have established an approach that transforms real-world, in-human treatment outcomes and safety data into extensive datasets to better characterize desirable and undesirable interactions between molecular pathways and drugs,” explains Dr. David Jackson, Chief Innovation Officer at Molecular Health and co-author on all three articles. “The studies demonstrate a standardized ...

ByMolecular Health GmbH


OncoDNA Launches OncoDEEP® Kit for Comprehensive Biomarker Testing of Solid Tumors

OncoDNA Launches OncoDEEP® Kit for Comprehensive Biomarker Testing of Solid Tumors

UNIQUE WORKFLOW SOLUTION INTEGRATING A COMPRENSIVE PAN-CANCER NGS PANEL POWERED BY TWIST BIOSCIENCE AND A BIOINFORMATICS SOFTWARE SUITE ONCODNA, A GENOMIC AND THERANOSTIC COMPANY SPECIALIZING IN PRECISION MEDICINE FOR THE TREATMENT OF CANCER AND GENETIC DISEASES, ANNOUNCED TODAY THE LAUNCH OF THE ONCODEEP KIT. ...

ByOncoDNA S.A.


SeqOne Genomics closes €20M series A to accelerate the deployment of its genomic medicine platform

SeqOne Genomics closes €20M series A to accelerate the deployment of its genomic medicine platform

The round, led by Omnes, Merieux Equity Partners, together with the Software Club and existing investors, Elaia and IRDI Capital Investissement, will enable SeqOne Genomics to accelerate its international sales and the development of new collaborative genomic analysis tools to facilitate communications between different disciplines in the medical team, in order ...

BySeqOne S.A.S.


Profacgen Enables Custom Bioinformatics Software Development for Researchers Worldwide

Profacgen Enables Custom Bioinformatics Software Development for Researchers Worldwide

Bioinformatics focuses on developing methods and software tools for understanding biological data using mathematical and statistical techniques. As an interdisciplinary research field, it has become an important part of biological research nowadays in the storage, analysis and interpretation of experimental data. The field of ...

ByProfacgen


Immunai Raises $215 Million to Accelerate Development of Its Immune-First Drug Actuary Platform

Immunai Raises $215 Million to Accelerate Development of Its Immune-First Drug Actuary Platform

Immunai, a New York-based biotech company, today announced a $215M Series B, increasing the company’s total funding to date to $295M. The new capital will be used to expand Immunai’s “drug actuary” platform for target validation and evaluation. “We have made great progress towards our core mission of understanding the immune system, which we believe is essential to ...

ByImmunai


Creative Enzymes Upgrades Metabolic Flux Analysis to Accelerate Your Project

Creative Enzymes Upgrades Metabolic Flux Analysis to Accelerate Your Project

Metabolic flux analysis (MFA) is an important analytical technique that can be used to examine the rate of production and consumption of metabolites in biological systems. ...

ByCreative Enzymes


Molecular Health and Gen Era Diagnostics agree to collaborate in the field of precision oncology in Turkey

Molecular Health and Gen Era Diagnostics agree to collaborate in the field of precision oncology in Turkey

We value the trust that Gen Era Diagnostics has placed in our technology and are convinced that patients in Turkey will benefit from it,” explains Thomas Holtrup, Senior Vice President, Head of Sales & Business Development, EMEA, at Molecular Health. MH Guide is an analysis software for interpreting molecular data from cancer patients. ...

ByMolecular Health GmbH


MH Guide 5.0: Software for therapy planning in precision oncology, now available with a comprehensive update

MH Guide 5.0: Software for therapy planning in precision oncology, now available with a comprehensive update

Molecular Health has launched the latest version of its analysis software MH Guide. This software, which is used by pathology laboratories and molecular tumor boards, now has improved search capabilities to identify patient- relevant clinical studies. ...

ByMolecular Health GmbH


Molecular Health and Universitätsmedizin Essen [Essen University Hospital] launch collaborative project to improve care for COVID-19 patients

Molecular Health and Universitätsmedizin Essen [Essen University Hospital] launch collaborative project to improve care for COVID-19 patients

About Molecular Health: Molecular Health is an international biotech IT company based in Heidelberg, Germany, that has been developing innovative software in the areas of in silico and precision medicine since 2004. Molecular Health’s solutions make it possible to transform large amounts of data into evidence-based, medically relevant decision support. ...

ByMolecular Health GmbH


Konyang University Hospital in South Korea relies on MH Guide for personalized cancer medicine

Konyang University Hospital in South Korea relies on MH Guide for personalized cancer medicine

MH Guide is an analysis software that helps molecular pathologists and oncologists interpret NGS data and make treatment decisions. ...

ByMolecular Health GmbH

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT